Overview of non-coding RNAs in breast cancers.
Breast cancer
Non-coding RNA
lncRNA
miRNA
piRNA
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
20
06
2022
revised:
18
07
2022
accepted:
02
08
2022
pubmed:
13
8
2022
medline:
13
8
2022
entrez:
12
8
2022
Statut:
ppublish
Résumé
Breast cancer in women is the second most common cancer and the fifth leading cause of cancer death worldwide. Although earlier diagnosis and detection of breast cancer has resulted in lower mortality rates, further advances in prevention, detection, and treatment are needed to improve outcomes and survival for women with breast cancer as well as to offer a personalized therapeutic approach. It is now well-established that non-coding RNAs (ncRNAs) represent 98% of the transcriptome but in-depth knowledge about their involvement in the regulation of gene expression is lacking. A growing body of research indicates that ncRNAs are essential for tumorigenesis by regulating the expression of tumour-related genes. In this review, we focus on their implication in breast cancer genesis but also report the latest knowledge of their theragnostic and therapeutic role. We highlight the need for accurate quantification of circulating ncRNAs which is determinant to develop reliable biomarkers. Further studies are mandatory to finally enter the era of personalized medicine for women with breast cancer.
Identifiants
pubmed: 35961269
pii: S1936-5233(22)00171-1
doi: 10.1016/j.tranon.2022.101512
pmc: PMC9382556
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
101512Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.